eliglustat sold brand name cerdelga medication used treatment gauchers disease discovered university michigan developed genzyme corp approved fda august commonly used tartrate salt compound believed work inhibition glucosylceramide according article journal american medical association oral substrate reduction therapy resulted significant improvements spleen volume hemoglobin level liver volume platelet count untreated adults gaucher disease type norman radin began exploring possibility inhibiting synthesis lipid substrates involved gauchers disease early collaboration laboratory jim shayman found several candidate inhibitors genzyme initially rejected candidates developed radin shayman news broke competitor developing new treatment gauchers disease licensed radinshayman patents eliglustat receive fda approval another years delay shayman speculated due company leaders fully committed developing drug would compete imiglucerase brand name cerezyme genzymes flagship treatment gauchers annual cost eliglustat taken orally twice day cerezyme cost intravenous medication taken twice manufacturing costs eliglustat slightly lower imiglucerase genzyme maintains higher prices orphan often paid order remain financially drug article relating gastrointestinal system stub help wikipedia expanding httpsenwikipediaorgwikieliglustat